Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Presentation from Erin Johnson to the Organization Development Network of Western NY.
For many organizations, the rate of change can be overwhelming as they try to respond to fluctuating and sometimes unstable market forces. More than ever, companies around the globe need leaders who are ready to rise to the challenge but research indicated that only a quarter of organizations are equipped to move managers into the executive ranks.
Presentation from Erin Johnson to the Organization Development Network of Western NY.
For many organizations, the rate of change can be overwhelming as they try to respond to fluctuating and sometimes unstable market forces. More than ever, companies around the globe need leaders who are ready to rise to the challenge but research indicated that only a quarter of organizations are equipped to move managers into the executive ranks.
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
The current structure of medical education emphasizes pedagogy related to the physician-patient relationship, and thus advocacy opportunities at this level. Patient and professional Advocacy Groups are important to the process of educating the marketplace on new therapies. Strong relationships with advocacy groups are important for educating the public on socially-sensitive conditions and treatment options.
Best Practices, LLC's study identifies effective practices in patient advocacy group collaboration and relationship management. This study also examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.
Download Full Report: http://bit.ly/2evZ0AE
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Healthcare is undergoing a transformation. Consumers want to make informed choices and take control of their lives, and pharma companies must be ready to meet their needs. This means building a new healthcare ecosystem that places the patient at its center, with the “person” fully engaged in his or her own healthcare. But with this move to person-centric healthcare, payers and providers are no longer the main decision makers.
So what does this mean for today’s marketers?
In this exclusive Social On Us webinar we discuss:
- Where marketing is failing to address healthcare concerns
- How “big data” is a change-driver for a new healthcare ecosystem
- New opportunities for predictive and preventative medical intervention
- Impact of digital healthcare on patient privacy
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
Bio-pharmaceutical organizations have long relied on medical education programs to provide latest medical knowledge to physicians and other health care professionals. However, recent compliance rules and regulations have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies, as well as some third-party providers of such services.
Best Practices, LLC, undertook benchmarking research to probe emerging medical education trends at top bio-pharmaceutical companies. In particular, this research provides benchmarks on the proper size, structure, activities performed, staffing, and investment for the Medical Education function.
Download Full Report: http://bit.ly/2cf5PYb
Benchmarking Professional Medical Education Excellence StructuresBest Practices
Continuing Medical Education (CME) programs serve to maintain, develop or enhance the skills, knowledge and professional performance & relationships that a physician uses to provide services to patients, public and the profession. However, recent compliance and transparency rules have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies as well as some third-party providers of such services. Critics such as Morris and Taitsman also prefer that the medical profession eliminate commercial support for CME.
Best Practices, LLC conducted this study to inform those who lead medical education programs at large bio-pharmaceutical companies about the proper size, resourcing and structure for the medical education function. The study looks into emerging Medical Education trends at medical device and pharmaceutical organizations regarding funding and program types.
Download Full Report: http://bit.ly/2bAUm6U
Care Management - Critical Component Of Effective Population HealthHealth Catalyst
In this first webinar, of a two-part series, Dr. Kathleen Clary will share how analytics can be used to answer these questions to ensure delivery of a well-organized and effective care management program.
Dr. Clary will discuss how analytics can enable:
Data integration from multiple EMRs and data sources
Patient stratification and intake
Care coordination
Patient engagement
Performance measurement
We look forward to you joining us!
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
To lead digital transformation, CIOs at pharmaceutical and medical device companies need to adopt new workstyles and mindsets, including C-level relationship-building and the ability to both catalyze innovation and find the talent to execute on it.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
The new product planning function within bio-pharmaceutical companies is tasked with the challenging role of delivering potential new products in shorter time frames and minimum development costs.
This Best Practices, LLC benchmarking report examines the role and impact of new product planning function on product commercialization. In particular, it examines the impact of structure, resources and activities of new product planning groups on product commercialization.
Download Full Report: http://bit.ly/2e8ErMD
More Related Content
Similar to Disease Awareness Program Excellence: Structure, Timing, Activities & Investment Needed for Effective Pipeline Support
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
The current structure of medical education emphasizes pedagogy related to the physician-patient relationship, and thus advocacy opportunities at this level. Patient and professional Advocacy Groups are important to the process of educating the marketplace on new therapies. Strong relationships with advocacy groups are important for educating the public on socially-sensitive conditions and treatment options.
Best Practices, LLC's study identifies effective practices in patient advocacy group collaboration and relationship management. This study also examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.
Download Full Report: http://bit.ly/2evZ0AE
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Healthcare is undergoing a transformation. Consumers want to make informed choices and take control of their lives, and pharma companies must be ready to meet their needs. This means building a new healthcare ecosystem that places the patient at its center, with the “person” fully engaged in his or her own healthcare. But with this move to person-centric healthcare, payers and providers are no longer the main decision makers.
So what does this mean for today’s marketers?
In this exclusive Social On Us webinar we discuss:
- Where marketing is failing to address healthcare concerns
- How “big data” is a change-driver for a new healthcare ecosystem
- New opportunities for predictive and preventative medical intervention
- Impact of digital healthcare on patient privacy
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
Bio-pharmaceutical organizations have long relied on medical education programs to provide latest medical knowledge to physicians and other health care professionals. However, recent compliance rules and regulations have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies, as well as some third-party providers of such services.
Best Practices, LLC, undertook benchmarking research to probe emerging medical education trends at top bio-pharmaceutical companies. In particular, this research provides benchmarks on the proper size, structure, activities performed, staffing, and investment for the Medical Education function.
Download Full Report: http://bit.ly/2cf5PYb
Benchmarking Professional Medical Education Excellence StructuresBest Practices
Continuing Medical Education (CME) programs serve to maintain, develop or enhance the skills, knowledge and professional performance & relationships that a physician uses to provide services to patients, public and the profession. However, recent compliance and transparency rules have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies as well as some third-party providers of such services. Critics such as Morris and Taitsman also prefer that the medical profession eliminate commercial support for CME.
Best Practices, LLC conducted this study to inform those who lead medical education programs at large bio-pharmaceutical companies about the proper size, resourcing and structure for the medical education function. The study looks into emerging Medical Education trends at medical device and pharmaceutical organizations regarding funding and program types.
Download Full Report: http://bit.ly/2bAUm6U
Care Management - Critical Component Of Effective Population HealthHealth Catalyst
In this first webinar, of a two-part series, Dr. Kathleen Clary will share how analytics can be used to answer these questions to ensure delivery of a well-organized and effective care management program.
Dr. Clary will discuss how analytics can enable:
Data integration from multiple EMRs and data sources
Patient stratification and intake
Care coordination
Patient engagement
Performance measurement
We look forward to you joining us!
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
To lead digital transformation, CIOs at pharmaceutical and medical device companies need to adopt new workstyles and mindsets, including C-level relationship-building and the ability to both catalyze innovation and find the talent to execute on it.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
The new product planning function within bio-pharmaceutical companies is tasked with the challenging role of delivering potential new products in shorter time frames and minimum development costs.
This Best Practices, LLC benchmarking report examines the role and impact of new product planning function on product commercialization. In particular, it examines the impact of structure, resources and activities of new product planning groups on product commercialization.
Download Full Report: http://bit.ly/2e8ErMD
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
Optimizing the resource and staffing levels at medical device companies enables Regulatory Affairs leaders to prioritize roles and responsibilities, thereby driving organizational growth.
Research & Consulting leader, Best Practices, LLC engaged Regulatory Affairs leaders at 32 leading medical device companies through a benchmarking survey to capture insights regarding current and future trends shaping the Regulatory Affairs function. This study delivers benchmarks around the critical drivers of regulatory performance excellence at medical device companies.
Download Full Report: http://bit.ly/2asHvQh
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
Biopharmaceutical and medical device companies rely on advisory board for strategic inputs and guidance on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. It is also important that the biopharmaceutical and medical device executives ensure quality of meetings and dialogue with advisory boards is excellent for maximum ROI.
This research from Best Practices, LLC showcase the best practices in advisory board management at mid-sized biopharmaceutical and medical device companies. It also highlights the top challenges, winning strategies and best practices for conducting advisory boards.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
Competitive Assessments and Clinical Landscape Assessments are crucial to the success of new products in the pharmaceutical industry. In order to inform busy executives quickly and effectively, market intelligence and analytics leaders must develop briefing templates that are clear, concise, and impactful.
This study identifies winning strategies for effectively informing senior leaders through Competitive Landscape Summaries and Clinical Development Profile Maps. The research will help executives to understand what the important elements to include are, and what are the best formats for two critical healthcare briefing templates: : 1) the Competitive Landscape Summary Map and 2) the Development Landscape Profile Map (often described as the Data Disclosure or Clinical Trials Progress Summary).
Read more at: http://www.best-in-class.com/bestp/domrep.nsf/products/developing-high-impact-communication-forms-to-brief-senior-leaders-optimizing-competitive-assessment-data-disclosure-summaries?OpenDocument
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
Managed Market’s role within the pharmaceutical industry has increased as the influence of payers is simultaneously increasing. Organizations are now being forced to reassess managed markets resources and market markets structures to optimize these groups and to encourage overall organizational success.
Best Practices, LLC designed this benchmarking study to assess managed markets role within small and mid-cap pharmaceutical companies. The overall goal of this project was to illustrate how to have the most impact within the organization while continuing to operate on lean resource levels.
Read more at: http://www.best-in-class.com/bestp/domrep.nsf/products/optimizing-managed-markets-function-roles-structures-resources-activities?OpenDocument
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Navigating Women's Health: Understanding Prenatal Care and Beyond
Disease Awareness Program Excellence: Structure, Timing, Activities & Investment Needed for Effective Pipeline Support
1. Disease Awareness Program Excellence:
Structure, Activities & Resources
Needed for Effective Pipeline Support
Best Practices, LLC
Strategic Benchmarking Research
2. Page | 2
Table of Contents
Executive Summary pgs. 4-10
Research Overview pg. 4
Participating Companies pg. 5
Key Findings Overview pg. 6
Key Insights Overview pg. 7
Overview of DA Timing pgs. 8
I. Participant Demographics pgs. 9-13
II. Program Effectiveness and Structure pgs. 14-19
III. Timing of Disease Awareness Activities pgs. 20-27
IV. Disease Awareness Budget and Spend pgs. 28-36
V. Involvement of Advocacy and Legal pgs. 37-45
VI. Social Media pgs. 46-53
VII. Best Practices and Pitfalls pgs. 54-56
VIII. Narratives from Interviews pgs. 57-66
VIIII. Key Findings pgs. 67-72
X. Appendix pgs. 73-78
About Best Practices, LLC pg. 79
3. Page | 3
Field Research & Insight Development:
Sixteen leaders at 16 leading pharmaceutical and
biotech organizations participated in this study. In
addition, one global communications firm representing
a biopharma client also participated.
Four executives also participated in deep-dive
operational interviews.
Additional secondary research
• Spotlight effective practices
around the timing, investment,
and activities for disease
awareness programs
• Present insights, best practices
and pitfalls that participants
have learned from past disease
awareness campaigns
Research Overview: Objectives & Methodology
Research Objectives:
Disease Awareness Program Timing and Investment
Timing for Beginning /Ending Campaigns and Spend Trends across Campaign Lifecycle
Peak Year Investment Level and Factors Influencing Resource Levels
Disease Awareness Activities and Critical Success Factors
Timing and Utilization of Activities and Activities Conducted on Social Media
Best Practices for Disease Awareness Programs
Business Objective:
Disease state awareness campaigns are one of the few ways to reach patients & physicians before a product is approved.
These campaigns set the table for future marketing efforts at product launch and post-launch. While some organizations
effectively utilize disease awareness programs, others struggle to connect campaigns to their targeted audiences.
4. Page | 4
Universe of Learning: 17 Top Companies Contributed to This Research
This study engaged 17 executives from leading pharmaceutical, biotech, and communications companies.
Benchmark Class
5. Page | 5
N=16
Given the job level of participants (44% director and 31% vice president), this study is presenting the perspectives of a
veteran group of executives with many years of experience.
Seventy-five Percent of Participants at Director or VP Level
% Respondents
Q.) Please list your current job title.
Director, all levels
44%
VP
31%
Manager
13%
Global Lead
6%
Head
6%
Participant Titles
6. Page | 6
N=17
While a centralized structure was the most common approach for participants (35%), other structures were also utilized
such as those taking a hybrid approach (36%), and a decentralized approach (30%).
No Organizational Structure Strongly Favored by Participants
% Respondents
Q.) Disease Awareness Organizational Structure Type: Which of the following models best describes the organizational
structure of your disease awareness program. (Choose one)
Other: Centralized through Marketing
35%
24%
18%
12%
12%
Centralized
Hybrid by business unit/division
Decentralized by geography
Decentralized by business unit/division
Hybrid by geography
Disease Awareness Organizational
Structure
7. Page | 7
N=17
Marketing has historically been the function most involved in disease state awareness and that still may be the case. But
interviews and secondary research point to medical as the future leader of disease awareness, given both the regulatory
environment and the expertise the function brings to the table. But as this chart shows, many functions are involved in DA.
Marketing Leads Disease Awareness for Most but Shift is to Medical
% Respondents
Q.) Disease Awareness Leadership and Involvement: In the following table, please indicate both: A) whether each function is
involved in disease awareness programs; and B) which functions take a leading role in disease awareness programs.
89%
83%
44%
50%
44%
28%
11%
61%
44%
17%
6%
22%
0%
6%
Marketing
Medical
Scientific Affairs
Legal
Patient Advocacy
Market Research
Other
Functional Involvement & Leadership in DA
Function(s) involved with Disease Awareness Programs Function(s) that lead Disease Awareness Programs
Other: Communications and Sales
“I think it has been shifting to
medical for a number of years now.
Medical tends to be more
conservative than commercial. I think
we are seen as more of a medical
issue and that’s the right way to see
it since we are trying to raise the
medical IQ of patients and physicians
around specifics of disease state.”
-- Senior Director, Market Research
8. Page | 8
N=16
Unbranded websites for HCPs and patients was clearly the most utilized disease awareness tool. The next most used DA
activity is presentations/handouts at conferences, closely followed by MSL presentations to HCPs. Two of the top three
activities involve personal, scientific interactions with HCPs.
Websites, Conferences, MSLs, and PowerPoint Decks are Key DA Tools
% Respondents
MOST UTILIZED DISEASE AWARENESS ACTIVITIES RANK 1 RANK 2 RANK 3
Unbranded website with disease information for HCPs & patients 53% 0% 7%
Power point deck for HCPs with disease state information (overview, description,
impact, prevalence)
20% 7% 0%
Disease state presentations or handouts at conferences and/or association
meetings
13% 27% 13%
Disease awareness documentaries 0% 13% 7%
Publications (advertorials, journal ads) 7% 7% 0%
Disease state presentations for HCPs at dinners or seminars 0% 13% 13%
Disease state information on advocacy group websites 0% 7% 13%
Disease awareness public relations campaigns 7% 0% 7%
MSL presentations to HCPs 0% 27% 33%
Other (Health policy events) 0% 0% 7%
Q.) Please indicate, in order, your three most heavily used disease awareness activities.
9. Page | 9
N=16
Most participants rely on marketing as the principal funding source for disease awareness, although brand teams were the
funding source for almost half. This chart may be a picture of transition – some participants spoke of the increasing role of
medical in disease awareness and predicted DA will go the way of medical education with medical affairs being the
principal function behind both activities and funding in the coming years.
Marketing Remains Primary Contributor to Disease Awareness Budget
% Respondents
Q.) Which of the following functions provide funding for your Disease Awareness program? (Choose one for each)
64%
46%
36%
31%
17%
11%
36%
31%
18%
46%
25%
44%
23%
45%
23%
58%
Marketing
Brand/Product Teams
Company-wide business unit
Medical
Regional or country-specific business unit
Regional or country-level organization (e.g. U.S., Emerging
Markets, EU)
Location of Budget for DSA Programs
Primary Contributor Secondary Contributor Not a Contributor
44%
10. Page | 10
While you can’t lump all of Europe together in terms of a regulatory approach, the UK is seen as especially sensitive to
promotional interpretations of disease state awareness information.
European Markets More Sensitive to Promotional Interpretations for DA
With Europe you have got to be more
general, for sure, and avoid anything
that would appear to be promotional in
any way, shape, or form. There’s a lot of
things, especially in the UK, that they
interpret as promotional. So it is just
one of those things you have got to
spend time on [regarding] ‘what do they
think of this?’
-Senior Director, Market Research
“
”
11. Page | 11
Key Findings
Few of the key findings and insights that emerged from this study are listed below:
No Single Structural Approach is Favored for Disease Awareness Programs: Participants aligned
equally with three structural approaches for disease state awareness programs: 35% centralized; 36%
hybrid; and 30% decentralized.
Marketing Leads Disease Awareness Programs for Most but Shift is to Medical: While marketing
was the function that led disease awareness programs for the largest percentage of participants (61%),
medical was not far behind at 44%. In addition, several participants said in interviews that they expect
medical to eventually become the principal leader of disease awareness efforts. Regulatory and
compliance issues as well as the expertise of the medical function were cited as the leading reasons for
the shift. Medical education went through a similar leadership change (commercial to medical) during the
past 10 years.
Marketing is Primary Contributor for Disease Awareness Programs: Most participants (64%) rely on
marketing as the principal funding source for disease awareness. Brand teams were second, with 46%
saying they were the primary contributor. As disease awareness leadership continues to move to
medical, the program funding will likely shift as well.
Patient Advocacy Groups Seen as Valuable Partners: Almost 80% of study participants think it is
highly important to create alliances with patient advocacy groups. At the same time, a majority also felt it
is highly important to build relationships with key advocates and work on disease awareness
websites/campaigns for/with advocacy groups.
12. Page | 12
Best Practices®, LLC is an internationally recognized thought leader in the field of best practice
benchmarking®. We are a research, consulting, benchmark database, publishing and advisory firm that
conducts work based on the simple yet profound principle that organizations can chart a course to superior
economic performance by leveraging the best business practices, operating tactics and winning strategies of
world-class companies.
6350 Quadrangle Drive, Suite 200
Chapel Hill, NC 27517
(Phone): 919-403-0251
www.best-in-class.com
Learn More About Our Company: